BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sauzeau V, Beignet J, Vergoten G, Bailly C. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma. Pharmacol Res 2022;:106220. [PMID: 35405309 DOI: 10.1016/j.phrs.2022.106220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Qi R, Huang Z. Novel diagnostic, therapeutic, and prognostic biomarkers for nonalcoholic steatohepatitis-derived hepatocellular carcinoma: Capable to overcome the heterogeneity-specific barrier.. [DOI: 10.21203/rs.3.rs-2367007/v1] [Reference Citation Analysis]
2 Khatoon F, Ali S, Kumar V, Elasbali AM, Alhassan HH, Alharethi SH, Islam A, Hassan MI. Pharmacological features, health benefits and clinical implications of honokiol. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2022.2120541] [Reference Citation Analysis]
3 Wang Z, Chen G. Insights about circadian clock in glioma: From molecular pathways to therapeutic drugs. CNS Neurosci Ther 2022. [PMID: 36066207 DOI: 10.1111/cns.13966] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Bailly C, Beignet J, Loirand G, Sauzeau V. Rac1 as a therapeutic anticancer target: Promises and limitations. Biochem Pharmacol 2022;203:115180. [PMID: 35853497 DOI: 10.1016/j.bcp.2022.115180] [Reference Citation Analysis]
5 Sauzeau V, Beignet J, Bailly C. Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder. Biomedicines 2022;10:1357. [PMID: 35740379 DOI: 10.3390/biomedicines10061357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]